The drug effectively reduced cholesterol in people with a hereditary high-cholesterol disorder and lowered the need for an expensive procedure, called apheresis therapy, to diminish cholesterol levels, the Tarrytown, NY-based biotechnology company said in a statement. Praulent was approved by regulators last year on the agreement that the companies continued studies of the drug with human subjects, according to MarketWatch .
http://ift.tt/2bw1YFd
No comments:
Post a Comment